Safety and immunogenicity of an mRNA COVID-19 vaccine administered to adults: A phase 2, randomized, active-controlled trial.
Robynne Wong, Anastasia Kuznetsova, Emna Baba et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2, randomized, active-controlled trial evaluated the safety and immunogenicity of two investigational mRNA COVID-19 vaccines in healthy adults aged 18 and older who had completed their primary vaccination series at least three months prior. The study found that both investigational vaccines elicited robust immune responses and had an acceptable safety profile, comparable to a licensed bivalent mRNA vaccine.
Key findings
- No vaccine-related serious adverse events or myocarditis/pericarditis cases were reported.
- A dose-dependent increase in Day 29 neutralizing titers against ancestral D614G and Omicron BA.4-5 was observed for the CV0701 mRNA vaccine.
- At Day 8, CD4+ T cells increased in all study groups, while CD8+ T cells increased in all but the lowest CV0701 dose group.
- Both investigational vaccines elicited robust humoral and cellular immunity comparable to a licensed bivalent mRNA vaccine.
Why it matters
Understanding the safety and immunogenicity of new COVID-19 vaccines is crucial for public health, especially as variants emerge. This study provides evidence that investigational vaccines can induce strong immune responses with a safety profile similar to existing options.